LT2527371T - Method for the treatment of glomerulonephritis - Google Patents

Method for the treatment of glomerulonephritis

Info

Publication number
LT2527371T
LT2527371T LTEP12174216.7T LT12174216T LT2527371T LT 2527371 T LT2527371 T LT 2527371T LT 12174216 T LT12174216 T LT 12174216T LT 2527371 T LT2527371 T LT 2527371T
Authority
LT
Lithuania
Prior art keywords
glomerulonephritis
treatment
Prior art date
Application number
LTEP12174216.7T
Other languages
Lithuanian (lt)
Inventor
Diane Marshall
Stevan Graham Shaw
Original Assignee
Ucb Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38640341&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2527371(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma S.A. filed Critical Ucb Pharma S.A.
Publication of LT2527371T publication Critical patent/LT2527371T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP12174216.7T 2007-09-06 2008-09-04 Method for the treatment of glomerulonephritis LT2527371T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0717337.0A GB0717337D0 (en) 2007-09-06 2007-09-06 Method of treatment

Publications (1)

Publication Number Publication Date
LT2527371T true LT2527371T (en) 2016-10-25

Family

ID=38640341

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12174216.7T LT2527371T (en) 2007-09-06 2008-09-04 Method for the treatment of glomerulonephritis

Country Status (14)

Country Link
US (1) US9321837B2 (en)
EP (2) EP2527371B1 (en)
CY (1) CY1118333T1 (en)
DK (1) DK2527371T3 (en)
ES (2) ES2595388T3 (en)
GB (1) GB0717337D0 (en)
HR (1) HRP20161460T1 (en)
HU (1) HUE031032T2 (en)
LT (1) LT2527371T (en)
PL (1) PL2527371T3 (en)
PT (1) PT2527371T (en)
RS (1) RS55281B1 (en)
SI (1) SI2527371T1 (en)
WO (1) WO2009030936A1 (en)

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DK1471142T3 (en) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimeric receptor libraries using phagemids
DE69233782D1 (en) 1991-12-02 2010-05-20 Medical Res Council Preparation of Autoantibodies on Phage Surfaces Starting from Antibody Segment Libraries
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
WO1994028159A1 (en) 1993-05-31 1994-12-08 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
WO1995020401A1 (en) 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
FR2716640B1 (en) 1994-02-28 1996-05-03 Procedes Machines Speciales Device for centering and blocking a workpiece with a view to running it in using an expansion lapper.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (en) 1996-01-24 1999-11-15 チッソ株式会社 Method for producing acryloxypropyl silane
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
DE69839517D1 (en) 1997-08-15 2008-07-03 Chugai Pharmaceutical Co Ltd PREVENTIVA OR ARZNEIA CONTAINING NEUTRALIZING ANTI-IL6 RECEPTOR ANTIBODIES FOR REDUCING URINARY PROTEINS IN SYSTEMIC LUPUS ERYTHEMATOSUS
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
AU2002346369B2 (en) 2001-11-14 2009-08-27 Eusa Pharma (Uk) Ltd Anti-IL-6 antibodies, compositions, methods and uses
EP1570267B1 (en) 2002-12-03 2011-10-12 UCB Pharma, S.A. Assay for identifying antibody producing cells
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005003169A2 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
ES2932398T3 (en) 2010-05-28 2023-01-18 Chugai Pharmaceutical Co Ltd Antitumor T cell response enhancer

Also Published As

Publication number Publication date
EP2527371B1 (en) 2016-08-17
WO2009030936A1 (en) 2009-03-12
RS55281B1 (en) 2017-03-31
EP2197915A1 (en) 2010-06-23
PT2527371T (en) 2016-11-23
EP2527371A1 (en) 2012-11-28
US9321837B2 (en) 2016-04-26
US20100310564A1 (en) 2010-12-09
SI2527371T1 (en) 2016-11-30
PL2527371T3 (en) 2017-02-28
CY1118333T1 (en) 2017-06-28
HUE031032T2 (en) 2017-06-28
GB0717337D0 (en) 2007-10-17
ES2429445T3 (en) 2013-11-14
DK2527371T3 (en) 2016-10-24
ES2595388T3 (en) 2016-12-29
HRP20161460T1 (en) 2016-12-16
EP2197915B1 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
HK1208237A1 (en) Methods for the treatment of gout
PL2303021T3 (en) Compounds for the treatment of cancer
IL212348A0 (en) Treatment method
AU2008272903A8 (en) Treatment for anxiety
GB0714363D0 (en) Treatment apparatus
EP2352515A4 (en) Method for the treatment of hemophilia
EP2032131A4 (en) Method of treatment
GB0610746D0 (en) Method of treatment
EP2341936A4 (en) METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
HK1203305A1 (en) Methods for treating psoriasis
EP2350641A4 (en) Method of treatment
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
GB2449996B (en) Effluent treatment process
IL193669A0 (en) Apparatus for the treatment of bruxism
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
GB0718684D0 (en) Treatment method
IL243809A0 (en) Process for the procuction of γ-ketosulfide compounds and γ-ketosulfide compounds
EP2182884A4 (en) Treatment apparatus
EP2164494A4 (en) Methods of treatment
GB0723100D0 (en) Treatment of HFnEF
PL2326551T3 (en) Apparatus for the treatment of wastewater
EP2209488A4 (en) Fgf9-related methods for treating anxiety
IL213287A0 (en) Treatment for glomerulonephritis
PL2527371T3 (en) Method for the treatment of glomerulonephritis
EP2203432A4 (en) Method of treatment